BFSG LLC’s ImmunityBio IBRX Stock Holding History

BFSG LLC’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.4K	Hold	1,300	–	–	﹤0.01%	562
2026 Q1	$9.97K	Hold	1,300	–	–	﹤0.01%	558
2025 Q4	$2.57K	Hold	1,300	–	–	﹤0.01%	633
2025 Q3	$3.2K	Hold	1,300	–	–	﹤0.01%	621
2025 Q2	$3.43K	Hold	1,300	–	–	﹤0.01%	585
2025 Q1	$3.91K	Buy	+1,300	New	+$3.94K	﹤0.01%	568

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BFSG LLC's IBRX Position: Q2 2026 in Review

BFSG LLC held its ImmunityBio (IBRX) position steady in Q2 2026 at 1,300 shares worth $11.4K. The position accounts for ﹤0.01% of the portfolio, ranked #562.

BFSG LLC first reported a position in IBRX in Q1 2025 and has held it in 6 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

BFSG LLC held 1,300 shares of ImmunityBio worth $11.4K as of Q2 2026.
BFSG LLC left its ImmunityBio share count unchanged in Q2 2026.
ImmunityBio made up ﹤0.01% of BFSG LLC's portfolio in Q2 2026, its #562 holding.
BFSG LLC first reported a position in ImmunityBio in Q1 2025 and has held it in 6 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on BFSG LLC's 13F filing for Q2 2026, filed 20 Jul 2026.